01574nas a2200277   4500000000100000008004100001260001300042653003800055653002700093653001200120653001100132653002100143653001200164653000900176653002400185653001800209653002900227653002500256100001900281700001700300245013100317300001100448490000600459520081700465022001401282       1983                            d  c1983 Apr10aAcetylmuramyl-Alanyl-Isoglutamine10aAdjuvants, Immunologic10aAnimals10aFemale10aImmunity, Innate10aleprosy10aMice10aMice, Inbred BALB C10aMycobacterium10aMycobacterium Infections10aMycobacterium leprae1 aKrahenbuhl J L1 aHumphres R C00aEffects of treatment with muramyl dipeptide on resistance to Mycobacterium leprae and Mycobacterium marinum infection in mice.  a329-390 v53 a<p>Studies were carried out to determine whether treatment of mice with the synthetic adjuvant muramyl dipeptide (MDP) afforded resistance to infection with Mycobacterium leprae or M. marinum in mice. Regardless of the timing, dose, or route of administration, there was no evidence that treatment with MDP or 3 of its analogs (desMDP, abuMDP, valMDP) enhanced resistance to food pad infection with M. leprae or M. marinum. In parallel studies, systemic treatment with Propionibacterium acnes failed to protect against either M. leprae or M. marinum. Administration of P. acnes locally into the foot pad afforded marginal resistance to M. marinum when injected prior to infection. Local treatment with P. acnes afforded marked resistance to growth of M. leprae, even when administered months after infection.</p>  a0162-3109